title: Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis.
abstract: A previous study has suggested that the combination KIR2DS2(+)/KIR2DL2(-) was related to increased risk for systemic sclerosis (SSc), while others have failed to reproduce this finding. Our objective was to study this matter further and test the association of other KIR genes with SSc. One hundred and ten SSc patients and 115 healthy bone marrow donors were enrolled in a case-control study. Blood was collected for DNA extraction; typing of 15 KIR genes and human leucocyte antigen-C (HLA-C) was made by polymerase chain reaction with sequence specific primers (PCR-SSP), followed by electrophoresis on agarose gel. Patients underwent clinical evaluation, serology, Doppler echocardiography and chest high-resolution computed tomography. The frequency of the inhibitory KIR2DL2 was significantly lower in patients [29.1% versus 65.2% in controls, P < 0.0001; odds ratio (OR) = 0.22, 95% confidence interval 0.12-0.40]. When combinations of activating and inhibitory KIR genes were analysed, the presence of KIR2DS2 in the absence of KIR2DL2 (KIR2DS2(+)/KIR2DL2(-)) was more frequent in patients than in controls (25.5% versus 1.7%, respectively; P < 0.0001; OR = 19.29, 4.24-122.26). However, the presence of both KIR2DS2 and KIR2DL2 (KIR2DS2(+)/KIR2DL2(+)) was more frequent in controls (57.4%) than in patients (28.2%, P < 0.0001), suggesting a preponderant protective effect of KIR2DL2 over KIR2DS2. Stratification for HLA-C1 status did not change these results. No statistically significant associations were found between KIR phenotypes and clinical and laboratory features of SSc. Our results suggest a protective role of KIR2DL2(+) phenotype and confirmed the association of the combination KIR2DS2(+)/KIR2DL2(-) with increased risk for SSc.
authors.affiliation: Postgraduate Program in Medicine: Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS Brazil. patysalim@gmail.com
authors.forename: P H
authors.initials: PH
authors.lastname: Salim
authors.forename: M
authors.initials: M
authors.lastname: Jobim
authors.forename: M
authors.initials: M
authors.lastname: Bredemeier
authors.forename: J A B
authors.initials: JA
authors.lastname: Chies
authors.forename: J
authors.initials: J
authors.lastname: Schlottfeldt
authors.forename: J C T
authors.initials: JC
authors.lastname: Brenol
authors.forename: L F
authors.initials: LF
authors.lastname: Jobim
authors.forename: R M
authors.initials: RM
authors.lastname: Xavier
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency / Q000276:immunology; D015236:HLA-C Antigens / Q000235:genetics* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D054340:Receptors, KIR / Q000235:genetics* / Q000276:immunology; D054343:Receptors, KIR2DL2 / Q000235:genetics* / Q000276:immunology; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000000981:diagnostic imaging / Q000235:genetics* / Q000276:immunology; D014463:Ultrasonography
chemical_list: D015236:HLA-C Antigens; C515077:KIR2DL2 protein, human; C433932:KIR2DS2 protein, human; D054340:Receptors, KIR; D054343:Receptors, KIR2DL2